amantadine has been researched along with rasagiline in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Büttner, T; Csoti, I; Kassubek, J; Reichmann, H; Riederer, P; Schulz, JB; Wüllner, U | 1 |
| Bozi, M; Christodoulou, C; Douzenis, A; Gasparinatos, G; Stamboulis, E; Stefanis, C; Stefanis, L; Stefanis, N | 1 |
| Sheehan, J; Thorpe, M; Wilson, L | 1 |
| Hernández-Vara, J; Salvado, M | 1 |
| Kulisevsky, J; Pagonabarraga, J | 1 |
| Canning, SD; Wang, XP; Zhang, LL | 1 |
| Afonso, ND; Chapela, D; Correia, AD; Outeiro, TF; Sousa, S; van der Linde, HC; Vaz, RL; Willemsen, R | 1 |
5 review(s) available for amantadine and rasagiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
Topics: Amantadine; Excitatory Amino Acid Antagonists; Humans; Indans; Memantine; Monoamine Oxidase; Monoamine Oxidase Inhibitors; N-Methylaspartate; Parkinson Disease; Piperidines; Selegiline | 2010 |
[Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
Topics: Amantadine; Antiparkinson Agents; Cardiovascular Diseases; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Food-Drug Interactions; Humans; Indans; Indoles; Levodopa; Mental Disorders; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Parkinson Disease; Serotonin Syndrome; Treatment Outcome | 2014 |
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Methylphenidate; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Selegiline; Treatment Outcome | 2016 |
4 other study(ies) available for amantadine and rasagiline
| Article | Year |
|---|---|
Isolated delusional syndrome in Parkinson's Disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Benserazide; Benzothiazoles; Catechols; Clonazepam; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Schizophrenia, Paranoid; Syndrome | 2010 |
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
Topics: Adult; Amantadine; Antiparkinson Agents; Benzothiazoles; Carbidopa; Catechols; Disruptive, Impulse Control, and Conduct Disorders; Drug Combinations; Female; Humans; Indans; Indoles; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Pramipexole; Selegiline | 2013 |
[Livedo reticularis secondary to amantadine in a patient with Parkinson disease].
Topics: Aged; Amantadine; Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Female; Humans; Indans; Levodopa; Livedo Reticularis; Parkinson Disease | 2014 |
Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Drug Repositioning; Indans; Isradipine; Larva; Levodopa; Locomotion; Motor Activity; Oxidopamine; Parkinson Disease; Phenotype; Zebrafish | 2020 |